Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis

Figure 4

Cost-effectiveness of rifaximin-α monotherapy compared with lactulose monotherapy in the first-line setting: (a) cost-effectiveness acceptability curve at a 10- to 14-day time horizon; (b) cost-effectiveness plane at a 10- to 14-day time horizon; (c) cost-effectiveness acceptability curve at a 5-year time horizon; and (d) cost-effectiveness plane at a 5-year time horizon. In panel (a) and (c), the horizontal axis displays willingness-to-pay budgetary thresholds to gain one additional QALY when using rifaximin-α plus lactulose in lieu of lactulose. In panel (b) and (d) the confidence intervals (CI) define the regions that contain 95% CI (yellow), 75% CI (green), and 50% CI (blue) of the samples that can be drawn from the underlying Gaussian distribution. Abbreviation: CI: confidence interval; QALY: quality-adjusted life-year.

(a)

(b)

(c)

(d)